Cannabis treatment for menopausal women

Share on facebook
Share on whatsapp
Share on linkedin
Share on email

Dear women, did you know that estrogen levels are directly related to endocannabinoid levels?

Menopause is a period in which a woman experiences physiological and psychological changes.

Cannabis treats mood swings – calms and improves mood, but it turns out that cannabis therapy is also an optimal alternative for women who can not take estrogen replacement because of a history of breast or ovarian cancer or heart disease, or even for menopausal women. Estrogen replacement is associated with an increased risk of heart attack, blood clots, gallstones, stroke, breast cancer and even Alzheimer’s disease.

Osteoporosis is one of the main reasons that doctors prescribe estrogen replacement drugs, but cannabis can be an excellent alternative because it also helps to stop bone loss by encouraging bone-building cells and inhibiting bone-destroying cells and also treating menopausal symptoms.Cannabis, especially cannabinoids CBG , CBD, CBC and THCV.

Women who can not use estrogen replacement drugs because of breast cancer risk or other medical conditions receive non-hormonal prescription drugs, including serotonin reuptake inhibitors, such as Effexor Prozac or Gabapentin, a drug used primarily for the treatment of epileptic seizures. Cannabis can be conditioned for all these drugs to successfully treat symptoms while reducing many unwanted side effects of these prescription drugs (including weight gain, gastrointestinal distress and decreased sexual function). Cannabis can increase the levels of serotonin and regulate body temperature, which can reduce the hot flashes and anxiety that exist in menopause.

Endocannabinoid System in Menopause:

The reduction in endocannabinoid levels may be the cause of some of the negative symptoms associated with menopause. This is not at all surprising, since estrogen levels are associated with endocannabinoid levels, and both reach a peak ovulation level, which does not occur in menopausal women. Fatty acid (FAAH), the enzyme that breaks down endocannabinoid anandam levels, analogous to THC, is regulated by estrogen. In fact, activation of estrogen receptors and cannabinoid receptors on the same cells, at the same time, often produces greater effects (synergism) than both of them themselves.

The endocannabinoid system, including the receptors CB1 and CB2 and endocannabinoid anandamide, is present in the ovaries and is responsible for maturation of the egg. Endocannabinoid deficiency probably causes early cessation of menstruation and the onset of menopause.

Estrogen recruits the endocannabinoid system and its activity in the brain reduces anxiety and depression. Menopause is less estrogen and therefore the endocannabinoid system is less active, resulting in decreased mood and ability to respond to stress.

The endocannabinoid system and CB2 receptors are found on osteoblast cells in the bones.

Women respond better to the pain-relieving effects of cannabis and THC when estrogen levels are at their highest level. Postmenopausal women have lower levels of estrogen and are less responsive to THC and require higher doses than premenopausal women to achieve the same pain relief and are more likely to be more likely to respond to men in their response to cannabis. Premenopausal women develop tolerance to THC rapidly, and may be more exposed to negative side effects of cannabis such as paranoia or anxiety. Postmenopausal women may remain on a stable dose of THC or cannabis in the long term, and may have less anxiety or paranoid symptoms than cannabis.

Contact us

Skip to content